中國生物製藥(01177.HK)"奧美沙坦酯氨氯地平片"獲藥品註冊證書
格隆匯12月14日丨中國生物製藥(01177.HK)公告,集團開發的新型降壓藥"奧美沙坦酯氨氯地平片"(商品名:天舒平)獲得中華人民共和國國家藥品監督管理局頒發藥品註冊證書,為該品種國內首仿獲批,且視同通過仿製藥質量和療效一致性評價。
奧美沙坦酯氨氯地平片適用於治療原發性高血壓,尤其適用於中重度高血壓以及單藥治療未達標的患者。奧美沙坦酯氨氯地平片是新一代的“血管緊張素受體拮抗劑+鈣通道阻滯劑(”ARB+CCB)單片複方製劑,具有降壓效果強、半衰期長、血藥濃度穩定的特點,每天用藥一次可滿足二十四小時長效、強效、平穩的降壓要求,同時可為心臟、腎臟等靶器官帶來多重保護。
集團在高血壓領域已有厄貝沙坦氫氯噻嗪片(依倫平)、奧美沙坦酯片(希佳)、安立生坦片(泰舒樂)等品牌產品,天舒平的獲批將進一步豐富集團心腦血管產品線,為患者提供更多用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.